Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome

R Bataller1, P Ginès, M Guevara

  • 1Department of Medicine, Hospital Clínic i Provincial, University of Barcelona, Catalunya, Spain.

Seminars in Liver Disease
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Street- and census-level NO<sub>2</sub> data for Barcelona with uncertainty and exceedance probability mapping.

Scientific data·2026
Same author

Incidence and Survival of Cutaneous Squamous Cell Carcinoma: A Spanish Multicenter Population-Based Study.

Actas dermo-sifiliograficas·2025
Same author

Corrigendum to "Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival" Eur J Cancer 229 (October) (2025) 115692.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Deciphering neutrophil dynamics: Enhanced phagocytosis of elastic particles and impact on vascular-targeted carrier performance.

Science advances·2025
Same journal

Hepatosystemic T cell licensing in MASLD-associated neuroinflammation.

Seminars in liver disease·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
See all related articles

Hepatorenal syndrome, a severe complication of cirrhosis, involves kidney failure due to altered blood flow. New diagnostic criteria and therapies show promise, but further research is needed.

Area of Science:

  • Hepatology
  • Nephrology
  • Gastroenterology

Background:

  • Hepatorenal syndrome (HRS) is a frequent complication in advanced cirrhosis with ascites.
  • It presents with renal failure, systemic hemodynamic changes, and vasoactive system alterations.
  • Renal hypoperfusion and vasoconstriction underlie the kidney dysfunction in HRS.

Purpose of the Study:

  • To summarize the current understanding of hepatorenal syndrome (HRS).
  • To highlight recent advancements in HRS definition and diagnostic criteria.
  • To discuss the prognosis and emerging therapeutic strategies for HRS.

Main Methods:

  • Review of existing literature on hepatorenal syndrome.
  • Analysis of recent proposals for HRS definition and diagnostic criteria.

Related Experiment Videos

  • Evaluation of current and novel treatment modalities for HRS.

    • Main Results:

    • HRS is characterized by renal vasoconstriction and hypoperfusion.
    • The proposed new criteria for HRS aim to improve diagnosis.
    • Liver transplantation offers the only definitive cure but has limitations.
    • Systemic vasoconstrictors and TIPS show potential as new therapies.

    Conclusions:

    • Hepatorenal syndrome is a critical complication of advanced liver disease with poor prognosis.
    • Revised diagnostic criteria may enhance research and clinical management.
    • Emerging therapies warrant further investigation to establish their efficacy.